Insider Buying: VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Buys 70,731 Shares of Stock

VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Martin Charles Faulkes bought 70,731 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were purchased at an average cost of $3.02 per share, with a total value of $213,607.62. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

VNRX traded down $0.06 during midday trading on Wednesday, hitting $3.02. The company had a trading volume of 714 shares, compared to its average volume of 85,509. VolitionRX Ltd has a 52 week low of $1.44 and a 52 week high of $3.63.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12).

VNRX has been the subject of several research analyst reports. Oppenheimer set a $5.00 price target on shares of VolitionRX and gave the company a “buy” rating in a research note on Wednesday, April 10th. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price target on shares of VolitionRX in a research note on Thursday, March 28th.

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in VolitionRX in the first quarter valued at $35,000. Renaissance Technologies LLC bought a new stake in VolitionRX in the first quarter valued at $37,000. Charles Schwab Investment Management Inc. bought a new stake in VolitionRX in the first quarter valued at $50,000. BlueCrest Capital Management Ltd bought a new stake in shares of VolitionRX during the first quarter worth about $81,000. Finally, Bank of New York Mellon Corp increased its position in shares of VolitionRX by 179.9% during the fourth quarter. Bank of New York Mellon Corp now owns 28,924 shares of the medical research company’s stock worth $52,000 after acquiring an additional 18,589 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Insider Buying: VolitionRX Ltd (NYSEAMERICAN:VNRX) Director Buys 70,731 Shares of Stock” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.wkrb13.com/2019/06/12/insider-buying-volitionrx-ltd-nyseamericanvnrx-director-buys-70731-shares-of-stock.html.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Featured Article: Fiduciary

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.